← Volver a los artículos

Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription

★ ★ ★ ★ ☆

Descripción general

Resumen del artículo › Explícamelo como si tuviera cinco años › Conflictos de intereses › Limitaciones identificadas › Explicación de la calificación › Conviene saber › Jerarquía temática › Información del archivo ›

Resumen del artículo

Título de Paperzilla
Emodin: The Weed That Starves Tumors (in Mice, at Least)

This study found that emodin, a natural compound from Chinese herbs, inhibits tumor angiogenesis and growth in triple-negative breast cancer (TNBC) models by increasing the expression of SerRS, a transcriptional repressor of VEGFA. Emodin directly interacts with NCOR2, leading to its dissociation from the SerRS promoter and subsequent SerRS activation.

Explícamelo como si tuviera cinco años

Scientists found that a special ingredient from some plants can stop a type of bad lump in the body from growing new "food roads." This makes it harder for the bad lump to get bigger.

Posibles conflictos de intereses

None identified

Limitaciones identificadas

Lack of human clinical data
The study primarily uses in vitro and in vivo models, lacking human clinical data to support the findings. Translational research is needed to confirm the efficacy and safety of emodin in human TNBC patients.
Poor pharmacokinetic properties of emodin
While emodin shows promising results in preclinical models, its poor pharmacokinetic properties, particularly low bioavailability, pose a significant challenge for clinical translation.
Multiple pharmacological activities of emodin
The study focuses on the anti-angiogenic effects of emodin, but its other pharmacological activities, such as cytotoxicity and induction of apoptosis, could confound the interpretation of the results. It's crucial to disentangle these effects to fully understand emodin's mechanism of action.
Incomplete mechanistic understanding
Although the study identifies NCOR2 as the direct target of emodin, further research is needed to fully elucidate the downstream signaling pathways and the precise mechanism by which emodin modulates NCOR2 activity.

Explicación de la calificación

This is a well-designed preclinical study with compelling in vitro and in vivo data supporting the anti-angiogenic and anti-tumor effects of emodin in TNBC models. The identification of NCOR2 as a direct target is a significant finding. However, the lack of human clinical data and the known pharmacokinetic limitations of emodin warrant a rating of 4 instead of 5.

Conviene saber

Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.

Explorar Pro →

Información del archivo

Título original: Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription
Subido: 14 jul 2025, 11:27:06
Privacidad: Público